Medicure Investor Relations Material
Latest events
Q3 2023
Medicure
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Medicure Inc
Access all reports
Medicure Inc. researches develops and commercializes human therapies for the cardiovascular market in the US. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. The company also sells UCERIS rectal foam for the induction of remission in patients with mild to moderate active distal ulcerative colitis, as well as develops deforolimus injection for acute myelogenous leukemia; roxadustat for anemia in chronic kidney disease; Apadenoson that is in Phase III clinical trials to diagnose coronary artery anomalies; and MC-4232, an oral endothelial receptor antagonist that is in Phase IIb clinical trial to treat congestive heart failure.
Key slides for Medicure Inc
Q1 2023
Medicure Inc
Q1 2023
Medicure Inc
Latest articles
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
Ticker symbol
Country
🇨🇦 Canada